Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy.

Balana, Carmen; Estival, Anna; Pineda, Estela

Balana, Carmen; Estival, Anna; Pineda, Estela.

Affiliation

Balana C; Catalan Institute of Oncology, Ctra Canyet s/n, 08916, Badalona, Spain. cbalana@iconcologia.net.
Estival A; Catalan Institute of Oncology, Ctra Canyet s/n, 08916, Badalona, Spain.
Pineda E; Hospital Clinic de Barcelona, Barcelona, Spain.

J Neurooncol ; 139(3): 779-780, 2018 Sep.

Article in En | MEDLINE | ID: mdl-29777419

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Bevacizumab/therapeutic use; Brain Neoplasms/drug therapy; Glioblastoma/drug therapy; Brain Neoplasms/pathology; Glioblastoma/pathology; Humans; Prognosis; Retreatment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma / Angiogenesis Inhibitors / Bevacizumab Type of study: Prognostic_studies Limits: Humans Language: En Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google